Abbott Receives FDA Clearance for FreeStyle Libre 3 CGM

Chicago – Abbott Laboratories has secured clearance from the U.S. Food and Drug Administration (FDA) for its FreeStyle Libre 3 continuous glucose monitoring (CGM) system. This latest device aims to assist individuals managing diabetes by providing real-time glucose level tracking.

The FreeStyle Libre 3 represents a significant advancement over previous generations. Abbott states the device is their smallest and most user-friendly CGM sensor to date. A primary focus of development was to simplify the user experience, eliminating the need for manual sensor assembly and reducing the physical footprint of the device.

Jean-Pierre Cole, an Abbott research fellow who spearheaded the development, described the process as a continuation of goals set during the conception of the initial FreeStyle Libre system. The ambition was consistently for a smaller, low-cost, and easy-to-use device. With Libre 3, this has been realized through a miniaturized sensor applicator that integrates the sensor directly, produced via an automated manufacturing process.

Abbott has been developing the FreeStyle Libre system for over 15 years. The company draws parallels between the impact of CGM technology and the introduction of color television, suggesting a similar shift in user experience and engagement. While traditional fingerstick tests have been the standard, advanced technologies like Libre 3 offer more precise and reliable glucose data, facilitating better health management for users.

The FDA clearance in the U.S. paves the way for the widespread adoption of the FreeStyle Libre 3. Abbott suggests the technology makes diabetes management more accessible and integrated into daily life, akin to how color television transformed the viewing experience.